References

  1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998 May 7;12(7):F51-8. PubMed | Google Scholar

  2. Thienemann F, Sliwa, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013 Dec;34(46):3538-46 Epub 2013 Oct 14. PubMed | Google Scholar

  3. Alassani A, Dovonou CA, Sossou E, Attinsounon CA, Gninkoun J, Wanvoegbe A et al. Prevalence, associated and predisposing factors of metabolic syndrome among people living with HIV on antiretroviral treatment in Porto Novo in 2014. Pan Afr Med J. 2015 Nov 24;22:296. PubMed | Google Scholar

  4. Dimodi HT, Etame C, Nguimkeng S, Mbappe FE, Ndoe, Tchinda et al. Prevalence of metabolic syndrome in HIV infected Cameroonian Patients. World Journal of AIDS. 2014; 4:84–92. Google Scholar

  5. Ayodele OE, Akinboro AO, Akinyemi SO, Adepeju AA, Akinremi OA, Alao CA, Popoola AA. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012 Oct;10(5):373-9. Epub 2012 Jul 16. PubMed | Google Scholar

  6. Adeyemi O, Rezai K, Bahk M, Badri S, Thomas-Gossain N. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS. 2008 Dec;22(12):941-5. PubMed | Google Scholar

  7. Zouiten, F, Ammari L, Chakroun M. Evaluation de la trithérapie antirétrovirale en Tunisie: étude multicentrique. Rev Tun Infectiol. 2007;1(1):12–19.

  8. Okome Nkoumou MML, Okome Essima R, Obiang Ndong GP, Okome Miame F. Bilan clinico-biologique des patients infectés par le VIH à la Fondation Jeanne Ebori de Libreville (2002-2005). Med Trop. 2007; 67: 357-362. Google Scholar

  9. Direction Générale de la Statistique et de la Comptabilité Nationale. Enquête Multiples Indicators Cluster Survey in Togo. 2006; 10-12.

  10. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. Recommandations du groupe d’experts. Médecine-Sciences, Ed Flammarion, Paris, p 402. 2002.

  11. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AD, El-Sadr W et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 2007 Apr 26;356(17):1723-35. PubMed | Google Scholar

  12. Cabarrot T. Pathologies métaboliques du patient infecté par le VIH, Nouvelles thérapies, effets secondaires, et Stratégie de prise en charge. Mémoire d’université Montpellier N°170/2005.

  13. Mildvan D, Machado SG, Wilets I, Grossberg SE. Endogenous interferon and triglyceride concentrations to assess response to zidovuline in AIDS and advanced AIQS-related complex. Lancet. 1992; 339: 453-6. PubMed | Google Scholar

  14. Schambelen M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommandations_of an international AIDS society-USA panel. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. Google Scholar

  15. Passalaris J, Sepkowitz K, Glesby M. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000; 31: 787-97. PubMed | Google Scholar

  16. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001 Jan;32(1):130-9. Epub 2000 Dec 15. PubMed | Google Scholar